You are here:

Category: 8.2 Drugs affecting the immune response

Name SMC ID No Manufacturer Status Sub. Type
 
alemtuzumab (MabCampath) 494/08 Bayer plc/Bayer Schering Pharma Marketing Authorisation Withdrawn Full submission
Avonex® liquid (Interferon beta 1a) 58/03 Biogen Idec Ltd Restricted Abbreviated Submission
axitinib (Inlyta) 855/13 Pfizer Ltd Not Recommended Full submission
belatacept (Nulojix) 786/12 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
belimumab (Benlysta) 775/12 GlaxoSmithKline UK Ltd Not Recommended Full submission
blinatumomab (Blincyto) 1145/16 Amgen Ltd Accepted Full submission
brentuximab vedotin (Adcetris) 845/12 Takeda UK Ltd Not Recommended Non submission
canakinumab (Ilaris) 658/10 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
canakinumab (Ilaris) 1210/16 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
canakinumab (Ilaris) 882/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
canakinumab (Ilaris) Arthritis 883/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
canakinumab (llaris) 926/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
daclizumab (Zinbryta) 1216/17 Biogen Idec Ltd Restricted Full submission
daratumumab (Darzalex) 1205/17 Janssen-Cilag Ltd Not Recommended Full submission
dimethyl fumarate (Tecfidera) 886/13 Biogen Idec Ltd Accepted Full submission
elotuzumab (Empliciti) 1183/16 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Non submission
fingolimod (Gilenya) 763/12 Novartis Pharmaceuticals UK Ltd Not Recommended Full submission
fingolimod (Gilenya) 763/12 Novartis Pharmaceuticals UK Ltd Restricted Resubmission
fingolimod (Gilenya) 992/14 Novartis Pharmaceuticals UK Ltd Restricted Full submission
fingolimod (Gilenya) 1038/15 Novartis Pharmaceuticals UK Ltd Accepted Full submission
glatiramer acetate (Copaxone) 1108/15 Teva UK Limited Accepted Abbreviated Submission
histamine dihydrochloride (Ceplene) 666/10 Meda Pharmaceuticals Ltd Not Recommended Full submission
idelalisib (Zydelig) 1212/16 Gilead Sciences Ltd Not Recommended Non submission
idelalisib (Zydelig) 1026/15 Gilead Sciences Ltd Restricted Full submission
idelalisib (Zydelig) 1039/15 Gilead Sciences Ltd Accepted Full submission
interferon beta-1a (Rebif) 825/12 Merck Serono Ltd Not Recommended Non submission
lenalidomide (Revlimid) 441/08 Celgene Ltd Restricted Resubmission
lenalidomide (Revlimid) 441/08 Celgene Ltd Not Recommended Full submission
lenalidomide (Revlimid) 441/08 Celgene Ltd Restricted Resubmission
lenalidomide (Revlimid) 1211/16 Celgene Ltd Not Recommended Non submission
lenalidomide (Revlimid) 942/14 Celgene Ltd Accepted Full submission
mifamurtide (Mepact) 621/10 Takeda UK Ltd Accepted Resubmission
Mycophenolate sodium (Myfortic®) 144/04 Novartis Pharmaceuticals UK Ltd Accepted Full submission
natalizumab (Tysabri®) 979/14 Biogen Idec Ltd Not Recommended Non submission
necitumumab (Portrazza) 1184/16 Eli Lilly and Company Ltd Not Recommended Non submission
nivolumab (Opdivo) 1187/16 Bristol-Myers Squibb Pharmaceuticals Ltd Restricted Full submission
nivolumab (Opdivo) 1188/16 Bristol-Myers Squibb Pharmaceuticals Ltd Not Recommended Full submission
obinutuzumab (Gazyvaro) 1008/14 Roche Accepted Full submission
obinutuzumab (Gazyvaro) 1219/17 Roche Accepted Full submission
ofatumumab (Arzerra) 1037/15 Novartis Pharmaceuticals UK Ltd Restricted Full submission
ofatumumab (Arzerra) 1237/17 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
olaparib (Lynparza) 1047/15 AstraZeneca UK Ltd Not Recommended Full submission
osimertinib (Tagrisso) 1214/17 AstraZeneca UK Ltd Restricted Full submission
panobinostat (Farydak) 1122/16 Novartis Pharmaceuticals UK Ltd Accepted Full submission
peginterferon beta 1a (Plegridy) 1018/14 Biogen Idec Ltd Accepted Full submission
Pegylated interferon alfa 2a (Pegasys®) 186/05 Roche Accepted Full submission
pegylated interferon alfa-2a (Pegasys) 871/13 Roche Superseded Abbreviated Submission
Pegylated interferon alfa-2a (Pegasys®) 10/02 Roche Restricted Full submission
pegylated interferon alfa-2b (Viraferon Peg) 794/12 MSD Superseded Abbreviated Submission
Pegylated interferon alfa-2b (ViraferonPeg®) 02/02 Schering-Plough Ltd Restricted Full submission
pembrolizumab (Keytruda) 1204/17 MSD Restricted Full submission
pembrolizumab (Keytruda) 1086/15 MSD Accepted Full submission
pembrolizumab (Keytruda) 1087/15 MSD Not Recommended Resubmission
pembrolizumab (Keytruda) 1087/15 MSD Not Recommended Full submission
ramucirumab (Cyramza) 1156/16 Eli Lilly and Company Ltd Not Recommended Non submission
ramucirumab (Cyramza) 1165/16 Lilly UK Not Recommended Non submission
rituximab (Mabthera) 675/11 Roche Restricted Full submission
rituximab (Mabthera) 894/13 Roche Restricted Full submission
rituximab subcutaneous (Mabthera) 975/14 Roche Restricted Full submission
ruxolitinib (Jakavi) 1166/16 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
tacrolimus (Envarsus) 1041/15 Chiesi Limited Accepted Abbreviated Submission
tacrolimus granules for suspension (Modigraf) 657/10 Astellas Pharma Ltd Restricted Abbreviated Submission
teriflunomide (Aubagio) 940/14 Genzyme Therapeutics Ltd Restricted Full submission

Back